Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

Most of my life I have been pretty stoic about getting injections or blood draws and even as a child I wasn’t bothered by syringes or needles. Now the thought ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Drugs such as trastuzumab (Herceptin), pertuzumab (Perjeta), and trastuzumab deruxtecan (Enhertu) have revolutionized HER2-positive breast cancer treatment. Additionally, immune checkpoint inhibitors ...

Despite everything I still feel very, very lucky. I have enough to cover my upcoming four rounds of Perjeta immunotherapy thanks to the generosity of friends and strangers. If not for that I would ...

And it’s important to note that in this space, in the breast cancer space, the largest drugs by far are infused drugs, whether it’s in HER2, Herceptin, PERJETA in the HER2 positive space or in ...

Phesgo is the combined therapy of Perjeta, Herceptin and ENHANZE, which is given in a single seven-minute subcutaneous injection for the treatment of breast cancer. We believe Phesgo is an ...

We also plan to launch a biosimilar Perjeta in the EU and in Latin America in 2026 with the U.S. following those launches. Lastly, we continue to see further business development opportunities to ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.26, expectations were $1.17 ...